EUCTR2006-001219-31-DE进行中（未招募）不适用
A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformin
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male, non-fertile female or female of childbearing potential using a medically approved birth control method.
- •A non-fertile female is defined as: post menopausal (12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/m); 6 weeks post bilateral oophorectomy with or without hysterectomy; post hysterectomy; or sterilized by tubal ligation.
- •A female of childbearing potential is defined as any woman physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means.
- •Medically approved birth control method include: hormonal contraceptives and IUD. Acceptable methods of contraception may include total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •Reliable contraception should be maintained throughout the study.
- •2.Patients with type 2 diabetes who have received metformin for at least 3 months and have been on a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to visit 1.
- •3.Agreement to maintain the same dose of metformin throughout the study.
- •4.Age 30-78 years.
- •5.Body mass index (BMI) in the range of 22-35 kg/m2 inclusive at visit 1.
- •6.HbA1c in the range of 6.5 to 9.0 % inclusive at visit 1.
- •7.FPG < 200 mg/dl (11.1 mmol/L) at visit 1.
- •8.Agreement to maintain prior diet and exercise habits during the full course of the study.
- •9.Ability to comply with all study requirements and signed informed consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnant or lactating female.
- •2.A history of:
- •Type 1 diabetes, diabetes that is a result of pancreatic injury, or other secondary forms of diabetes, e.g., Cushing’s syndrome and acromegaly.
- •Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma).
- •3.Evidence of significant diabetic complications, e.g., symptomatic autonomic neuropathy or gastroparesis.
- •4.Acute infections which may affect blood glucose control within 4 weeks prior to visit 1 and other concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
- •5.A history of:
- •Torsades de Pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation.
- •percutaneous coronary intervention within the past 3 months.
- •any of the following within the past 6 months: myocardial infarction (MI) (If the visit 1 ECG reveals patterns consistent with a MI and the date of the event cannot be determined, then the patient can enter the study at the discretion of the investigator and the sponsor); coronary artery bypass surgery; unstable angina; or stroke.
- •6.Congestive heart failure requiring pharmacologic treatment.
- •7.Any of the following ECG abnormalities:
- •second degree AV block (Mobitz 1 and 2)
- •third degree AV block
- •prolonged QTc (> 500 msec)
- •8.Malignancy including leukemia and lymphoma (not including basal cell skin cancer) within the last 5 years.
- •9.Liver disease such as cirrhosis or chronic active hepatitis.
- •10.Significant renal dysfunction (see also exclusion criteria 21 laboratory abnormalities).
- •11.Donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks. In addition, patients with anemia, as defined by hemoglobin < 12.0 mg/dL at visit 1, will be excluded.
- •12.Contraindications and warnings according to the country specific label for metformin not listed in the other exclusion criteria.
- •13.Treatment with any oral anti-diabetic other than metformin within 3 months prior to visit 1
- •14.Insulin treatment for longer than 10 days within the past 6 months.
- •15.Treatment with growth hormone or similar drugs.
- •16.Chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
- •17.Treatment with class Ia, Ib and Ic or III anti-arrhythmics.
- •18.Use of other investigational drugs at visit 1, or within 30 days or 5 half-lives of visit 1, whichever is longer, unless local health authority guidelines mandate a longer period.
- •19.Treatment with any drug with a known and frequent toxicity to a major organ system within the past 3 months (i.e., cytostatic drugs).
- •20.Any of the following significant laboratory abnormalities:
- •ALT, AST greater than 2 times the upper limit of the normal range (ULN) at visit 1, confirmed by a repeat measure within 3 working days.
- •Total bilirubin greater than 2 times ULN and direct bilirubin greater than the upper limit of the normal range at visit 1, confirmed by a repeat measure within 3 working days.
- •A positive Hepatitis B test (surface antigen -HBsAg).
- •A positive Hepatitis C test (HCV antibodies).
- •Serum creatinine levels = 1.5 mg/dL (132 µmol/L) males, = 1.4 mg/dL (123µmol/L) females, or a history of abnormal creatinine clearance.
- •Clinically significant TSH outside of normal range at visit 1; thyroid hormone replacement is allowed if the dosa
研究者
相似试验
进行中（未招募）
不适用
A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on glucagon counterregulatory response during hypoglycemia in patients with type 2 diabetesType II DiabetesEUCTR2006-001218-34-SEovartis Pharma Services AG28
尚未招募
Unknown
A single-center, double-blind, randomized, placebo-controlled clinical study of Shuhe granule in the treatment of chronic insomnia with qi-blood disharmony and deficiency of both heart and kidneyinsomniaITMCTR2024000035Guangdong Provincial Hospitai of Chinese Medicine
已完成
不适用
A single-center, double-blind, randomized, placebo-controlled Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-1014-6470 in healthy subjects, including food effect, mass balance, and metabolite profilinginflammatory diseasesNL-OMON48421Idorsia Pharmaceuticals Ltd88
已完成
不适用
A single-center, double-blind, randomized, placebo-controlled, 13-week study to evaluate the efficacy and safety of one capsule of XTEND-LIFE compared to placebo, and an extended four-week trial to assess its benefit when combined with ezetimibe 10 mg per dayHypercholesterolemiaISRCTN36282240Connecticut Clinical Research LLC (USA)60
进行中（未招募）
1 期
Oxytocin TrialMedDRA version: 20.0Level: LLTClassification code 10003805Term: AutismSystem Organ Class: 100000004873Autism Spectrum DisorderEUCTR2013-003067-59-ITAZIENDA OSPEDALIERA G. BROTZ30